• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Eledon Pharmaceuticals Inc.

    7/29/25 1:13:10 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELDN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Eledon Pharmaceuticals Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    28617K101

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    28617K101


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    26,417.00
    7Sole Dispositive Power

    3,269,735.00
    8Shared Dispositive Power

    48,648.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,318,383.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.54 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Eledon Pharmaceuticals Inc
    (b)Address of issuer's principal executive offices:

    19900 MacArthur Blvd, Suite 550, Irvine, CA, 92612
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    28617K101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3318383
    (b)Percent of class:

    5.54  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    26417

     (iii) Sole power to dispose or to direct the disposition of:

    3269735

     (iv) Shared power to dispose or to direct the disposition of:

    48648

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:07/29/2025
    Get the next $ELDN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELDN

    DatePrice TargetRatingAnalyst
    6/18/2025$9.00Buy
    H.C. Wainwright
    1/28/2025$9.00Buy
    Guggenheim
    5/13/2022$25.00 → $15.00Overweight
    Cantor Fitzgerald
    11/24/2021$35.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ELDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Eledon Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00

    6/18/25 7:57:38 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Eledon Pharmaceuticals with a new price target

    Guggenheim initiated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00

    1/28/25 7:12:35 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Eledon Pharmaceuticals with a new price target

    Cantor Fitzgerald resumed coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $15.00 from $25.00 previously

    5/13/22 9:03:12 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    5/13/24 5:04:15 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    SEC Filings

    View All

    SEC Form 10-Q filed by Eledon Pharmaceuticals Inc.

    10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    8/14/25 5:11:12 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-Q/A filed by Eledon Pharmaceuticals Inc.

    10-Q/A - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    8/14/25 5:08:29 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-K/A filed by Eledon Pharmaceuticals Inc.

    10-K/A - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    8/14/25 4:46:26 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

    Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025 Cash, cash equivalents and short-term investments of $107.6 million as of June 30, 2025 IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its second quarter 2025 operating and financial results and reviewed recent business highlights. "We are proud to enter the second half of the year with strong momentum as we have achieved all of our key miles

    8/14/25 4:20:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

    Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may improve 5-year graft survival vs. current standard of care Tegoprubart continues to be well tolerated with no cases of death, graft loss, drug related tremor, or new-onset diabetes Conference call to be held today at 4:30 p.m. ET IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated data from the Company's ongoing open-label Phase 1b trial evaluating tegoprubar

    8/6/25 4:01:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

    IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025. To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conferen

    7/30/25 4:05:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Gros David-Alexandre C

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    1/13/25 5:30:09 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kirk Allan

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    1/13/25 5:30:03 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President Perrin Steven

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    1/13/25 5:30:06 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Leadership Updates

    Live Leadership Updates

    View All

    Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

    Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2023 opera

    3/28/24 4:01:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

    Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated  Dosed first participants in Phase 2 BESTOW trial in kidney transplantation  Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key Highlights Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection i

    1/4/24 4:40:44 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

    Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights. "We were thrilled recently to report updated results from our ongoing Phase 1b study that continue to validate tegoprubart's potential as an immuno

    11/9/23 4:01:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Financials

    Live finance-specific insights

    View All

    Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

    Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may improve 5-year graft survival vs. current standard of care Tegoprubart continues to be well tolerated with no cases of death, graft loss, drug related tremor, or new-onset diabetes Conference call to be held today at 4:30 p.m. ET IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated data from the Company's ongoing open-label Phase 1b trial evaluating tegoprubar

    8/6/25 4:01:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

    IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025. To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conferen

    7/30/25 4:05:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

    Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90 supporting tegoprubart's potential to protect organ function in patients undergoing kidney transplantation Eledon will host a conference call today at 5:00 p.m. ET IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results

    11/2/23 9:05:00 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eledon Pharmaceuticals Inc.

    SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    11/14/24 4:51:31 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

    SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    11/5/24 4:17:26 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

    SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    11/5/24 11:44:57 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care